The life sciences firm, which reported over $1.2 billion in net sales for fiscal year 2026, continues to supply reagents and diagnostic tools to laboratories across the globe. With a workforce of approximately 3,000 employees and operations spanning 34 international locations, the company serves a broad customer base ranging from academic researchers to major biopharmaceutical entities. The board intends to evaluate future cash distributions on a quarterly basis, though management cautions that these decisions remain subject to operational risks, market competition, and shifts in research funding. Bio-Techne currently organizes its extensive product catalog under three primary brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.